Clovis Oncology (Clovis Oncology) Debt-to-EBITDA : -3.80 (As of Sep. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clovis Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $663.8 Mil. Clovis Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $16.8 Mil. Clovis Oncology's annualized EBITDA for the quarter that ended in Sep. 2022 was $-179.2 Mil. Clovis Oncology's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was -3.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Clovis Oncology's Debt-to-EBITDA or its related term are showing as below:

CLVSQ's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.375
* Ranked among companies with meaningful Debt-to-EBITDA only.

Clovis Oncology Debt-to-EBITDA Historical Data

The historical data trend for Clovis Oncology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Debt-to-EBITDA Chart

Clovis Oncology Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.84

-1.64

-1.91

-2.84

Clovis Oncology Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-EBITDA	Get a 7-Day Free Trial															-2.73	-2.92	-3.28	-2.77	-3.80

Competitive Comparison of Clovis Oncology's Debt-to-EBITDA

For the Biotechnology subindustry, Clovis Oncology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clovis Oncology's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's Debt-to-EBITDA falls into.

Clovis Oncology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clovis Oncology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(11.914	+	626.459)	/	-224.759
	=	-2.84

Clovis Oncology's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(663.829	+	16.791)	/	-179.176
	=	-3.80

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.

Clovis Oncology (OTCPK:CLVSQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Clovis Oncology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Clovis Oncology (Clovis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301

Website

https://www.clovisoncology.com

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Executives

Thomas C. Harding	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read	officer: See Remarks	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl	officer: See remarks	5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov	director	1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair	director	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy	director, officer: President and CEO	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen	director	TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham	director	AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104